Zobrazeno 1 - 10 of 48 pro vyhledávání: '"C, Phares"'
1
The interplay between vitamin D and COVID-19: protective or bystander?
Autor: H F, Hetta, K, Muhammad, E A, El-Masry, A E, Taha, E A, Ahmed, C, Phares, H A, Kader, Y, Waheed, A M, Zahran, R, Yahia, A Kh, Meshaal, G, El-Saber Batiha
Publikováno v: European review for medical and pharmacological sciences. 25(4)
The world is currently facing the COVID-19 pandemic, caused by the novel Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). Due to a lack of specific treatment and prophylaxis, protective health measures that can reduce infection severity
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::151d4dacf000c8dd6d7bc1399d4f8b61
https://pubmed.ncbi.nlm.nih.gov/33660833
Zobrazit plný text záznamu
2
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
3
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
4
Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer
Autor: Margaret Edison, Seth M. Steinberg, Ruby Phelps, R. I. Linnoila, Barnett S. Kramer, M Lesar, James L. Mulshine, Daniel C. Ihde, John C. Phares, Adi F. Gazdar
Publikováno v: Journal of Clinical Oncology. 12:2022-2034
PURPOSE We performed a prospective randomized clinical trial to determine whether higher doses of etoposide and cisplatin (EP) yield more complete responses or longer survival in small-cell lung cancer (SCLC) patients. PATIENTS AND METHODS Ninety pat
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8839d7d37b0314af88bfe398c3158434
https://doi.org/10.1200/jco.1994.12.10.2022
Zobrazit plný text záznamu
5
Limited stage small cell lung cancer treated with concurrent hyperfractionated chest radiotherapy and etoposide/cisplatin
Autor: John C. Nesbitt, Daniel C. Ihde, Adi F. Gazdar, Ruby Phelps, John D. Minna, Harvey I. Pass, Catherine Salem, Bruce E. Johnson, John C. Phares, R. Ilona Linnoila, James L. Mulshine, Eli Glatstein, May Lesar, Margaret Edison
Publikováno v: Lung Cancer. 9:S21-S26
Forty-one previously untreated patients with limited-stage small cell lung cancer (SCLC) entered a combined-modality study. Patients were initially treated with etoposide and cisplatin and concurrent chest radiotherapy. Patients then received two mor
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::48b34b524e5c5bbb434aee85bd985c91
https://doi.org/10.1016/0169-5002(93)90002-f
Zobrazit plný text záznamu
6
Phase I trial of dihydrolenperone in lung cancer patients: A novel compound within vitro activity against lung cancer
Autor: Chi-Taou Tsai, Joyce Stocker, Mae Jean Miller, Robert J. Parker, Julie Baltz, Robert H. Shoemaker, Ruby Phelps, Adi F. Gazdar, James L. Mulshine, John C. Phares, Anne Bastian, Bruce E. Johnson, Daniel C. Ihde
Publikováno v: Investigational New Drugs. 11:29-37
Antitumor activity of the butyrophenone dihydrolenperone in non-small cell lung cancer was initially suggested by in vitro screening against tumor cells derived from fresh surgical samples using the human tumor colony-forming assay. We have completed
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a2860cfc9b1051cf41f0b4ef08a93a8
https://doi.org/10.1007/bf00873907
Zobrazit plný text záznamu
7
Treatment of advanced-stage Hodgkin's disease: alternating noncrossresistant MOPP/CABS is not superior to MOPP
Autor: Robert C. Young, Susan M. Hubbard, J C Phares, V T DeVita, P L Duffey, A W Bastian, Elaine S. Jaffe, Dan L. Longo, Peter H. Wiernik
Publikováno v: Journal of Clinical Oncology. 9:1409-1420
One hundred twenty-five assessable patients with advanced-stage Hodgkin's disease were randomized to receive mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) or MOPP alternating with lomustine (CCNU), doxorubicin, bleomycin, and stre
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f65999288c344dd8680e3a0d36bcebf6
https://doi.org/10.1200/jco.1991.9.8.1409
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Late extramedullary relapse following bone marrow transplant for AML presenting as acute renal failure and leukemic ascites
Autor: D A, Riseberg, K P, Mulvey, W L, Dahut, J N, Frame, J C, Phares
Publikováno v: Bone marrow transplantation. 14(6)
A 22-year-old woman with AML in remission for 3.5 years after BMT relapsed with extramedullary disease presenting as leukemic ascites and recurrent obstructive renal failure. The duration of remission post-transplant and the absence of bone marrow in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::ab4b86d8ba5eef9df52bd325a40a4924
https://pubmed.ncbi.nlm.nih.gov/7711663
Zobrazit plný text záznamu
10
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure
Autor: P L Duffey, Robert C. Young, Dan L. Longo, J C Phares, Walter J. Urba, Eli Glatstein, V T DeVita, Elaine S. Jaffe, Daniel C. Ihde, Susan M. Hubbard
Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 10(2)
PURPOSE The study was undertaken to evaluate clinical prognostic factors, probability of response to therapy, duration of response, and overall survival of patients with Hodgkin's disease relapsing from a chemotherapy-induced complete remission. PATI
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7cae244336f4a65e259f8c5880d28b50
https://pubmed.ncbi.nlm.nih.gov/1732422
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje